Eli Lilly Slashes Zepbound Prices: A Game-Changer for Weight Loss Medication Access

Eli Lilly Slashes Zepbound Prices: A Game-Changer for Weight Loss Medication Access

Eli Lilly Slashes Zepbound Prices: A Game-Changer for Weight Loss Medication Access

Eli Lilly Slashes Zepbound Prices: A Game-Changer for Weight Loss Medication Access

Eli Lilly Slashes Zepbound Prices: A Game-Changer for Weight Loss Medication Access

Sep 25, 2024

Sep 25, 2024

CaptainMD Staff

CaptainMD Staff

Weight loss woman with red dress curly red hair eyeglasses glasses in office hands on hips Zepbound
Weight loss woman with red dress curly red hair eyeglasses glasses in office hands on hips Zepbound
Weight loss woman with red dress curly red hair eyeglasses glasses in office hands on hips Zepbound
Weight loss woman with red dress curly red hair eyeglasses glasses in office hands on hips Zepbound
Weight loss woman with red dress curly red hair eyeglasses glasses in office hands on hips Zepbound

Eli Lilly has taken a significant step to make its popular weight loss drug Zepbound more accessible and affordable by announcing a new program offering substantial discounts on single-dose vials of Zepbound. This helps address the high demand and cost concerns surrounding weight loss medications.

Key Points of the Discount Program

  • Steep Price Reduction: Eli Lilly is now offering single-dose vials of Zepbound at a 50% or greater discount compared to list prices of other GLP-1 medications for obesity.

  • Pricing Details:

    • 2.5mg dose: $399 for a four-week supply ($99.75 per vial)

    • 5mg dose: $549 for a four-week supply ($137.25 per vial)

  • Availability: The discounted vials are available through Eli Lilly's LillyDirect program.

Prices are subject to change. Please check the Eli Lilly website for more information here.

Expanding Access and Affordability

This initiative aims to broaden access to Zepbound for several groups:

  1. Patients without employer coverage

  2. Those who need to self-pay outside of insurance

  3. Individuals ineligible for the Zepbound savings card program

Ensuring Legitimate Use

To prevent misuse and ensure patient safety, Eli Lilly has implemented several measures:

  • Prescription Requirement: Patients must have a valid, on-label prescription from their healthcare provider.

  • Multi-Step Verification: This process ensures the medication is dispensed only for legitimate medical use, not cosmetic weight loss.

Impact on the Weight Loss Medication Market

The introduction of discounted Zepbound vials is likely to intensify competition in the weight loss medication market:

  • Zepbound generated $1.24 billion in revenue in Q2 2024.

  • By 2030, Zepbound is forecast to generate $27.2 billion in sales, surpassing Novo Nordisk's Wegovy.

Industry and Expert Reactions

The move has been well-received by healthcare professionals and advocacy groups:

  • The Obesity Action Coalition praised Eli Lilly for expanding access to obesity treatment.

  • Experts hope this initiative will encourage other companies to lower prices for self-pay obesity medications.

By offering Zepbound at a significant discount, Eli Lilly is addressing the critical issues of affordability and accessibility in obesity treatment. This move not only helps patients access necessary medication but also puts pressure on the industry to make weight loss drugs more affordable overall.

For more information, visit the Zepbound savings options from Eli Lilly here.

Please note that our practice is not affiliated with Zepbound or Eli Lilly.

Share on X
Share on Facebook
Share on LinkedIn
Share on X
Share on Facebook
Share on LinkedIn

Disclaimer

This article is for informational purposes only. It is not intended to replace advice, diagnosis, treatment, or services from a medical professional.

To book an online doctor appointment today, visit our booking page here. In the event of an emergency, please call 911 (US only).

Latest posts
Latest posts
Latest posts
Latest posts